Samsung Bioepis and Teva Expand Biosimilar Partnership to Six Candidates Including Fasenra, Ilaris

The Quick Take

• Samsung Bioepis and Teva expanded their strategic partnership to advance up to six biosimilar drug candidates
• The agreement covers SB41, a biosimilar referencing Fasenra (benralizumab), and SB44, referencing Ilaris (canakinumab)
• An option for four additional biosimilar candidates signals a long-term pipeline commitment to challenge multiple branded drug monopolies

Samsung Bioepis and Teva Pharmaceuticals have expanded their existing biosimilar partnership to encompass up to six drug candidates, including two already named: SB41 targeting AstraZeneca's Fasenra (benralizumab, used in severe asthma) and SB44 targeting Novartis's Ilaris (canakinumab, used in rare inflammatory conditions). The partnership structure follows Samsung Bioepis's established playbook of combining its South Korean bioengineering capabilities with Teva's global commercial distribution network to bring biosimilars to market across North America, Europe, and other regulated markets.

The strategic logic for both parties is clear: Samsung Bioepis gains guaranteed commercial scale and Teva's payer relationships, while Teva diversifies its revenue away from generic small-molecule drugs — a segment under sustained pricing pressure — toward the higher-margin biosimilar space. The two additional biosimilar candidates covered by option agreements suggest the partnership has a well-populated research pipeline, with candidates likely targeting other high-revenue immunology or oncology biologics.

For the competitive landscape, the most significant near-term impact is on AstraZeneca and Novartis, which will face pricing pressure in the Fasenra and Ilaris markets as regulatory submissions advance. The timeline from partnership announcement to commercial launch typically runs 3-5 years for biosimilars, meaning the revenue impact on both originator companies will be felt in the 2029-2031 window. Indian biosimilar makers should monitor the EMA and FDA submission schedules closely — Samsung Bioepis's regulatory track record suggests SB41 and SB44 will follow an aggressive timeline.

Synthesized from 1 source.